Download PDF
Thromb Haemost 1995; 73(03): 405-412
DOI: 10.1055/s-0038-1653789
Original Articles
Coagulation
Schattauer GmbH Stuttgart

Inhibition of Thrombin by Antithrombin III and Heparin Cofactor II In Vivo

Longbin Liu
1   The Canadian Red Cross Society, Blood Services, Hamilton, Canada
2   Department of Pathology, McMaster University, Hamilton, Canada, New York
,
Lori Dewar
1   The Canadian Red Cross Society, Blood Services, Hamilton, Canada
,
Yingqi Song
2   Department of Pathology, McMaster University, Hamilton, Canada, New York
,
Myron Kulczycky
2   Department of Pathology, McMaster University, Hamilton, Canada, New York
,
Blajchman A Morris
1   The Canadian Red Cross Society, Blood Services, Hamilton, Canada
2   Department of Pathology, McMaster University, Hamilton, Canada, New York
3   Department of Pathology, McMaster University, Hamilton, Canada, New York
,
John W Fenton
4   Department of Health, Albany, U.S.A.
,
Maureen Andrew
5   Department of Paediatrics, McMaster University, Hamilton, Canada, New York
,
M Delorme
3   Department of Pathology, McMaster University, Hamilton, Canada, New York
,
Jeffrey Ginsberg
3   Department of Pathology, McMaster University, Hamilton, Canada, New York
,
Klaus T Preissner
6   Department of Haemostasis Research, Kerckhoff-Klinik, Max-Plank-Gesellschaft, Bad Nauheim, Germany
,
Frederick A Ofosu
1   The Canadian Red Cross Society, Blood Services, Hamilton, Canada
2   Department of Pathology, McMaster University, Hamilton, Canada, New York
› Author Affiliations
Further Information

Publication History

Received27 July 1994

Accepted after resubmission 29 November 1994

Publication Date:
09 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

The critical role of thrombin in the pathogenesis of venous and arterial thrombosis, and the effectiveness of glycosaminoglycans as antithrombotic drugs are well known. Antithrombin III is a major inhibitor of thrombin and augmentation of its inhibitory actions by heparin is the basis for the clinical uses of heparin. Recent clinical and experimental studies have demonstrated that another glycosaminoglycan, dermatan sulfate, is an effective antithrombotic drug. Dermatan sulfate catalyses the inhibition of thrombin by heparin cofactor II. The concentrations of heparin cofactor II are higher in the plasmas of individuals with congenital antithrombin III deficiency and pregnant women than controls. The role of heparin cofactor II as a physiologic thrombin inhibitor is unknown. Enzyme-linked immunosorbent assays were used to quantify thrombin-heparin cofactor II and thrombin-antithrombin III endogenous to the plasmas of adult antithrombin III-Hamilton deficient subjects, their siblings with normal antithrombin III levels, pregnant women at term and 3 to 5 days after delivery. Both thrombin-antithrombin III and thrombin-heparin cofactor II complexed with vitronectin were detected in all the plasmas. Significantly, the concentrations of thrombin-heparin cofactor II-vitronectin were higher in the plasmas of congenital antithrombin III deficient subjects and in pre- and post-delivery plasmas than those of normal subjects. In addition, the concentrations of thrombin-heparin cofactor II decreased 3 to 5 days after delivery, reflecting the disappearance of the catalytically active dermatan sulfate elaborated by the placenta. Thus, heparin cofactor II normally inactivates thrombin in vivo, with its role increasing in conditions associated with high levels of heparin cofactor II and/or dermatan sulfate.

 

  • References

  • 1 Fenton II JW. Thrombin. Ann NY Acad Sei 1986; 485: 5-15
    CrossrefPubMedGoogle Scholar
  • 2 Teitel JM, Bauer KA, Lau HK, Rosenberg RD. Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F1+2 fragment and thrombin-antithrombin complex. Blood 1982; 59: 1086-1097
    PubMedGoogle Scholar
  • 3 Pelzer H, Schwarz A, Stuber W. Determination of human prothrombin activation fragment 1+2 in plasma with an antibody against a synthetic peptide. Thromb Haemost 1991; 65: 153-159
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Pratt CW, Church FC. Antithrombin: Structure and function. Semin Thromb Haemost 1990; 28: 3-9
    PubMedGoogle Scholar
  • 5 Travis J, Salvesen GS. Human plasma proteinase inhibitors. Ann Rev Biochem 1983; 52: 655-709
    CrossrefPubMedGoogle Scholar
  • 6 Bjork I, Danielsson A. Antithrombin and related inhibitors of coagulation proteinase. In: Proteinase inhibitors. Barrett AT, Salvesen GS. eds Elsevier; Amsterdam, The Netherlands: 1986. pp 489-513
    Google Scholar
  • 7 Hirsh J, Piovella F, Pini M. Congenital antithrombin III deficiency incidence and clinical features. Am J Med 1989; 87 Suppl (Suppl. 03) B 4S-38S
    CrossrefPubMedGoogle Scholar
  • 8 Rosenberg RD, Bauer KA. Thrombosis in inherited deficiencies of antithrombin, protein C and protein S. Hum Pathol 1987; 18: 253-262
    CrossrefPubMedGoogle Scholar
  • 9 Pelzer H, Schwarz A, Heimburger N. Determination of Human thrombinantithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost 1988; 59: 101-106
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Hoek JA, Sturk A, ten Cate JW, Lamping RG, Berends F, Borm JJ J. Laboratory and clinical evaluations of an assay of thrombin-antithrombin III complexes in plasma. Clin Chem 1988; 34: 2058-2062
    PubMedGoogle Scholar
  • 11 Hoek JA, Nurmohamed MT, ten Cate JW, Büler HR, Knipscheer HC, Hamelynck KJ. et al. Thrombin-antithrombin III complexes in the prediction of deep vein thrombosis following total hip replacement. Thromb Haemost 1989; 62: 1050-1052
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Boneu B, Bes G, Pelzer H, Sié P, Boccalon H. D-Dimers, Thrombin antithrombin III complexes, and prothrombin fragments 1+2: Diagnostic value in clinically suspected deep vein thrombosis. Thromb Haemost 1991; 65: 28-32
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Tollefsen DM, Majerus DW, Blank MK. Heparin cofactor II: Purifications and properties of a heparin inhibitor of thrombin in human plasma. J Biol Chem 1982; 257: 2161-2169
    PubMedGoogle Scholar
  • 14 Buchanan MR, Boneu B, Ofosu FA, Hirsh J. The relative importance of thrombin inhibition and factor Xa inhibition to the antithrombotic effects of heparin. Blood 1985; 65: 198-201
    PubMedGoogle Scholar
  • 15 Lane DA, Ryan K, Ireland H, Curtis JR, Nurmohamed MT, Krediet RT, Roggekamp MC, Stevens P, ten Cate JW. Dermatan sulphate in haemodialysis. Lancet 1992; 339: 334-335
    CrossrefPubMedGoogle Scholar
  • 16 Agnelli G, Cosmi B, Filippo PD, Ranucci V, Veschi F, Longetti M, Renga C, Barzi F, Gianese F, Luciano L, Rinonapoli E, Nenci G. A randomised, double-blind, placebo-controlled trial of dermatan sulphate for prevention of deep vein thrombosis in hip fracture. Thromb Haemost 1992; 67: 203-208
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Tran TH, Marbet GA. Duckert F: Association of hereditary heparin cofactor II deficiency with thrombosis. Lancet 1985; 2: 413-414
    PubMedGoogle Scholar
  • 18 Sie P, Dupouy D, Pichon J, Boneu B. Constitutional heparin cofactor II deficiency associated with recurrent thrombosis. Lancet 1985; 2: 414-416
    PubMedGoogle Scholar
  • 19 Andrew M, Mitchell LBerry, Paes B, Delorme M, Ofosu FA, Burrows R, Khambalia B. An anticoagulant dermatan sulfate proteoglycan circulates in the pregnant woman and her fetus. J Clin Invest 1992; 89: 321-326
    CrossrefPubMedGoogle Scholar
  • 20 Miller-Andersson M, Borg H, Andersson LO. Purification of antithrombin III by affinity chromatography. Thromb Res 1974; 5: 439-446
    CrossrefPubMedGoogle Scholar
  • 21 Preissner KT, Wassmuth R, Muller-Berghaus G. Physiochemical characterization of human S-protein and its function in the blood coagulation system. Biochem J 1985; 231: 349-355
    CrossrefPubMedGoogle Scholar
  • 22 Shattil SJ, Gunningham M, Hoxie JA. Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood 1987; 70: 307-15
    PubMedGoogle Scholar
  • 23 de Boer HC, Groot PG, Bouma BN, Preissner KT. Ternary vitronectin- thrombin-antithrombin III complexes in human plasma. J Biol Chem 1993; 268: 1279-1283
    PubMedGoogle Scholar
  • 24 Demers C, Ginsberg JS, Henderson P, Ofosu FA, Weitz JI, Blajchman MA. Measurement of markers of activated coagulation in antithrombin III deficient subjects. Thromb Haemost 1992; 67: 542-544
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Demers C, Ginsberg JS, Hirsh J, Henderson P, and BlajchmanM. Prevelance of thrombosis in antithrombin-III-deficient individuals: report of a large kindred and literature review. Ann Int Med 1992; 116: 754-761
    CrossrefPubMedGoogle Scholar
  • 26 Demers C, Henderson P, Blajchman MA, Wells MJ, Mitchell L, Johnston M, Ofosu FA, Fernandez-Rachubinski F, Andrew M, Hirsh J, Ginsberg JS. An antithrombin III assay based on factor Xa inhibition provides a more reliable test to identify congential antithrombin III deficiency than an assay based on thrombin inhibition. Thromb Haemost 1993; 69: 231-235
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Shifman MA, Pizzo SV. The in vivo metabolism of antithrombin III and antithrombin III complexes. J Biol Chem 1982; 257: 3243-3248
    PubMedGoogle Scholar
  • 28 Bauer KA, Goodman TL, Kass BL, Rosenberg RD. Elevated factor Xa activity in the blood of asymptomatic patients with congenital antithrombin deficiency. J Clin Invest 1985; 76: 826-836
    CrossrefPubMedGoogle Scholar
  • 29 de Boer HC, Preissner KT, Bouma BN, de Groot PG. Binding of vitronectin-thrombin-antithrombin III complex to human endothelial cells is mediated by the heparin binding site of vitronectin. J Biol Chem 1992; 267: 2264-2268
    PubMedGoogle Scholar
  • 30 Gouin-Thibault I, Dewar L, Kulczycky M, Sternback M, Ofosu FA. Factor Xa-antithrombin III complexes in plasma: relationship to prothrombin activation in vivo (submitted for publication).
    PubMedGoogle Scholar
  • 31 Reinthaller A, Mursh-Edlmayer G, and TatraG. Thrombin-antithrombin III complex levels in normal pregnancy with hypertensive disorders and after delivery. Br J Obstet Gynaecol 1990; 97: 506-510
    CrossrefPubMedGoogle Scholar
  • 32 de Boer K, ten Gate JW, Sturk A, Borm JJ J, Treffers PE. Enhanced thrombin generation in normal and hypertensive pregnancy. Am J Obstet Gynecol 1989; 160: 95-100
    CrossrefPubMedGoogle Scholar
  • 33 Massauh M, Jatoi A, Gordon EM, Ratnoff OD. Heparin cofactor II activity in plasma during pregnancy and oral contraceptive use. J Lab Clin Med 1989; 114: 697-699
    PubMedGoogle Scholar
  • 34 Knauer DJ, Thompson JA, Cunningham DD. Protease nexins: cell secreted proteins that mediate the binding, internalization and degradation of regulatory serine proteases. J Cell Physiol 1983; 117: 385-396
    CrossrefPubMedGoogle Scholar